Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis provided background on a study presented at ACTRIMS 2026 focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

The associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with MS at the 2026 ACTRIMS Forum. [WATCH TIME: 3 minutes]

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

The staff neurologist at Cleveland Clinic discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

The senior research investigator at the New York Stem Cell Foundation discussed how human iPSC-based models can help dissect the cellular mechanisms underlying PIRA and progressive disability in multiple sclerosis. [WATCH TIME: 3 minutes]

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]

Experts discussed how aging impacts multiple sclerosis management, treatment decisions, and overall patient health. [WATCH TIME: 5 minutes]

Experts discussed the current and future applications of AI and machine learning in multiple sclerosis research and clinical care, highlighting both opportunities and limitations. [WATCH TIME: 9 minutes]

Experts discussed the promise and uncertainty surrounding BTK inhibitors and CAR T-cell therapy in addressing progressive multiple sclerosis. [WATCH TIME: 8 minutes]

Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS.

Sumaira Ahmed, founder and executive director of The Sumaira Foundation, discussed how FDA-approved therapies transformed the NMOSD treatment landscape and highlighted ongoing challenges in patient care.

The founder and executive director of the Sumaira Foundation emphasized the critical role of lifestyle factors such as sleep, exercise, and nutrition for maintaining brain health in patients with NMOSD. [WATCH TIME: 3 minutes]

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]

The assistant professor in the department of neurology at Mount Sinai discussed distinguishing cognitive impairment in MS from AD emphasizing orientation as a key differentiator. [WATCH TIME: 5 minutes]

The professor of neurology at University of Colorado School of Medicine talked about the challenges of telehealth and device-based data collection in clinical practice. [WATCH TIME: 4 minutes]

Despite advancements in NMOSD treatments, the founder and executive director of the Sumaira Foundation discussed how misdiagnosis, delayed diagnosis, and disparities in care remain significant challenges. [WATCH TIME: 4 minutes]

The professor of neurological sciences at the University of Vermont discussed the work of the MS Differential Diagnosis Consortium, highlighting efforts to refine MS differential diagnosis and improve clinical accuracy. [WATCH TIME: 8 minutes]

The medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed findings from phase 3 trials suggesting that baseline PRLs can predict disability accumulation and may serve as biomarkers for treatment response to tolebrutinib. [WATCH TIME: 6 minutes]